Carfilzomib - Onyx Pharmaceuticals
Alternative Names: Kyprolis; ONO-7057; PR-171Latest Information Update: 30 Jul 2024
At a glance
- Originator Proteolix
- Developer AbbVie; Amgen; Dana-Farber Cancer Institute; Genentech; GSK; Janssen Biotech; M. D. Anderson Cancer Center; Ohio State University Comprehensive Cancer Center; Ono Pharmaceutical; Onyx Pharmaceuticals; Phoenix Children's Hospital; Roswell Park Cancer Institute; The Innovative Therapies for Children with Cancer; Therapeutic Advances in Childhood Leukemia & Lymphoma; University of Alabama at Birmingham; University of Birmingham; University of California at San Francisco; University of California, Davis; University of Rochester; University of Texas M. D. Anderson Cancer Center
- Class Antineoplastics; Epoxy compounds; Oligopeptides; Small molecules
- Mechanism of Action Proteasome inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Multiple myeloma
Highest Development Phases
- Marketed Multiple myeloma
- Phase III Waldenstrom's macroglobulinaemia
- Phase II Mantle-cell lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma; Prostate cancer; Renal cell carcinoma
- Phase I/II Diffuse large B cell lymphoma; Peripheral T-cell lymphoma; Small cell lung cancer; Solid tumours
- No development reported Leukaemia; Lymphoid leukaemia; Lymphoma; Non-Hodgkin's lymphoma; Systemic lupus erythematosus
Most Recent Events
- 28 Jun 2024 Onyx Pharmaceuticals completes the phase I/II trials in Precursor cell lymphoblastic leukaemia-lymphoma (Combination therapy, Monotherapy, In adolescents, In adults, In children, In infants, Second-line therapy or greater) in Turkey, Taiwan, Sweden, South Korea, Singapore, Russia, Romania, Portugal, Portugal, Poland, Hong Kong, Greece, Greece, Brazil, Bulgaria, Argentina, Thailand, South Africa, Saudi Arabia, Norway, Mexico, Czech Republic, Colombia, Chile (IV) (NCT02303821) (EudraCT2014-001633-84)
- 12 Apr 2024 Amgen and Arbeitsgemeinschaft medikamentoese Tumortherapie completes a phase II trial in Multiple myeloma (Combination therapy, First line therapy) in Austria and Germany (NCT02891811) (EudraCT2016-000475-24)
- 07 Nov 2023 Stanford University and Amgen completes a phase-I trial in Solid Tumours and Leukaemia (In infants, children, Adolescents, In adults, Second-line therapy or greater)in Canada and USA (NCT02512926)